Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Plinabulin |
| Synonyms | |
| Therapy Description |
Plinabulin (NPI-2358) is a diketopiperazine derivative that disrupts microtubule organization, leading to cell cycle arrest in tumor cells and collapse of tumor vasculature (PMID: 16317287, PMID: 31811421). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Plinabulin | NPI-2358 | Antimicrotubule Agent 14 | Plinabulin (NPI-2358) is a diketopiperazine derivative that disrupts microtubule organization, leading to cell cycle arrest in tumor cells and collapse of tumor vasculature (PMID: 16317287, PMID: 31811421). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03102606 | Phase II | Plinabulin Pegfilgrastim | Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective-1) | Completed | USA | 3 |
| NCT05130827 | Phase II | Plinabulin | Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT) | Active, not recruiting | USA | 0 |